Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD; GAUSS-3 Investigators. Nissen SE, et al. Among authors: catapano a. Clin Cardiol. 2016 Mar;39(3):137-44. doi: 10.1002/clc.22518. Epub 2016 Mar 4. Clin Cardiol. 2016. PMID: 26946077 Free PMC article. Clinical Trial.
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Polis AB, et al. Metab Syndr Relat Disord. 2009 Dec;7(6):601-10. doi: 10.1089/met.2009.0009. Metab Syndr Relat Disord. 2009. PMID: 19929597 Clinical Trial.
How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort.
Poli A, Tragni E, Casula M, Filippi A, Diotti R, Brignoli O, Cricelli C, Catapano AL; CHECK Group. Poli A, et al. Among authors: catapano al. Nutr Metab Cardiovasc Dis. 2012 Apr;22(4):327-36. doi: 10.1016/j.numecd.2010.06.009. Epub 2010 Sep 29. Nutr Metab Cardiovasc Dis. 2012. PMID: 20884190
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, Rosenberg E, Tershakovec AM. Davidson MH, et al. J Clin Lipidol. 2008 Dec;2(6):436-46. doi: 10.1016/j.jacl.2008.10.003. Epub 2008 Oct 22. J Clin Lipidol. 2008. PMID: 21291777
697 results